Key Points Compass Pathways was named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech, and Fierce Healthcare. The recognition highlights organizations and…
August 31, 2026
Numinus Wellness Reports 29% Quarterly Revenue Growth as Practitioner Training Accelerates
Key Points Q4 fiscal 2025 revenue increased 29% sequentially to C$2.33 million. Gross profit rose 63.5% from the prior quarter to C$1.42 million. Gross margin…
Key Points Definium Therapeutics reported positive Phase 3 results for DT120, its investigational LSD-based treatment for generalized anxiety disorder, or GAD. A single DT120 dose…
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a clinical-stage pharmaceutical company developing oral small-molecule therapeutics for neurologic, inflammatory, metabolic, and neuropsychiatric disorders, announced on July 30, 2026…
AtaiBeckley Inc. (NASDAQ: ATAI) is ripping higher today, up about 33% to 7.125, after Eli Lilly announced a deal to acquire the company. Lilly is…
AtaiBeckley just had a breakout moment, with its share price soaring on news that Eli Lilly is in talks to buy the psychedelic drug developer….
BlackBerry Limited (NYSE: BB) is putting in a strong session today, with the stock up about 20% to 10.37 from a prior close of 8.62….
June 23, 2026
Definium Therapeutics Achieves Historic Phase 3 Milestone with LSD-Based Depression Treatment
Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company, announced positive topline results from its Phase 3 Emerge study on June 22, 2026. The…
Compass Pathways (NASDAQ: CMPS) surged to a two-year valuation high in mid-May 2026 following major financial and clinical milestones. This aggressive market activity reflects a…
PharmaTher Holdings Ltd. (OTCQB: PHRRF) is currently positioning its proprietary PharmaPatch™ and PatchPrint™ platforms to benefit from major U.S. regulatory catalysts. This strategic alignment for…
Shares of Enveric Biosciences, Inc. (Nasdaq: ENVB) are exploding higher, trading at $4.2332, up 132.59% on the day after gapping up from a previous close of $1.82 and touching an intraday high…
The Presidential Executive order signed Saturday, directs federal health and drug agencies to accelerate research and review of psychedelic therapies for serious mental illness, with…